文献速递眼底病与葡萄膜炎

生物类似药SB11与参照雷珠单抗治疗新生血管性年龄相关性黄斑变性的1年III期随机临床试验结果

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
PubMed 文献 · Br J Ophthalmol · 2021-10-16

这项多中心、随机、双掩码、平行组III期等效性研究纳入705例新生血管性年龄相关性黄斑变性患者,按1:1随机接受每月玻璃体腔注射0.5 mg SB11或参照雷珠单抗。52周结果显示两组在最佳矫正视力变化和中央亚区厚度变化上的等效性保持稳定,安全性和免疫原性特征可比,支持SB11与参照雷珠单抗的生物类似性。

要点

  • SB11与参照雷珠单抗在52周时最佳矫正视力变化差异为-0.6字母(90% CI -2.1至0.9),等效性稳定。
  • 中央亚区厚度变化差异为-14.9 µm(95% CI -25.3至-4.5),两组可比。
  • 眼部治疗中出现的不良事件发生率SB11组32.0% vs 参照雷珠单抗组29.7%,未观察到新安全性信号。

核心结论

  • 该研究52周长期结果进一步支持SB11与参照雷珠单抗之间建立的生物类似性。

研究设计与样本

  • 多中心、随机、双掩码、平行组III期等效性研究,纳入705例≥50岁新生血管性年龄相关性黄斑变性患者,每例设一只研究眼。
  • 参与者按1:1随机接受每月玻璃体腔注射0.5 mg SB11或参照雷珠单抗,评估至52周。

主要发现

  • 705例随机参与者中(SB11组351例,参照雷珠单抗组354例),634例(89.9%;SB11组307例,参照雷珠单抗组327例)完成至第52周的研究。
  • 第52周时,SB11与参照雷珠单抗在全分析集中最佳矫正视力自基线变化的最小二乘均值差为-0.6字母(90% CI -2.1至0.9)。
  • 第52周时,中央亚区厚度自基线变化的治疗差异为-14.9 µm(95% CI -25.3至-4.5)。
  • 眼部治疗中出现的不良事件发生率SB11组为32.0%,参照雷珠单抗组为29.7%;严重眼部治疗中出现的不良事件发生率分别为2.9%和2.3%。
  • 截至第52周,抗药抗体累积发生率SB11组为4.2%,参照雷珠单抗组为5.5%,药代动力学和免疫原性特征可比。

关键数值与推荐

  • 主要疗效等效性在至第52周保持稳定,SB11与参照雷珠单抗之间可比。

临床怎么用

  • SB11可作为参照雷珠单抗的生物类似药用于新生血管性年龄相关性黄斑变性的每月玻璃体腔注射治疗,长期疗效和安全性特征可比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD). METHODS: Setting: Multicentre. Design: Randomised, double-masked, parallel-group, phase III equivalence study. Patient population: ≥50 years old participants with nAMD (n=705), one 'study eye'. INTERVENTION: 1:1 randomisation to monthly intravitreal injection of 0.5 mg SB11 or RBZ. Main outcome measures: Visual efficacy endpoints, safety, immunogenicity and PK up to 52 weeks. RESULTS: Baseline and disease characteristics were comparable between treatment groups. Of 705 randomised participants (SB11: n=351; RBZ: n=354), 634 participants (89.9%; SB11: n=307; RBZ: n=327) completed the study until week 52. Previously reported equivalence in primary efficacy remained stable up to week 52 and were comparable between SB11 and RBZ. The adjusted treatment difference between SB11 and RBZ in full analysis set at week 52 of change from baseline in best-corrected visual acuity was -0.6 letters (90% CI -2.1 to 0.9) and of change from baseline in central subfield thickness was -14.9 µm (95% CI -25.3 to -4.5). The incidence of ocular treatment-emergent adverse events (TEAEs) (SB11: 32.0% vs RBZ: 29.7%) and serious ocular TEAE (SB11: 2.9% vs RBZ: 2.3%) appeared comparable between treatment groups, and no new safety concerns were observed. The PK and immunogenicity profiles were comparable, with a 4.2% and 5.5% cumulative incidence of antidrug antibodies up to week 52 for SB11 and RBZ, respectively. CONCLUSIONS: Longer-term results of this study further support the biosimilarity established between SB11 and RBZ.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bressler NM, Veith M, Hamouz J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021. PMID: 34656987. doi:10.1136/bjophthalmol-2021-319637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。